Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. - Tiedt R; King FJ; Stamm C; Niederst MJ; Delach S; Zumstein-Mecker S; Meltzer J; Mulford IJ; Labrot E; Engstler BS; Baltschukat S; Kerr G; et al. (Cell reports, 2023)